Stichting Wageningen Research
Wageningen, Gelderland, 6708 WG, Netherlands
NCT Number: NCT04590768
This study aims to assess the impact of daily intake of 11 grams of Fermotein™ on gastrointestinal complaints and several other health related biomarkers. Furthermore, consumer acceptance is investigated. The study has a randomized parallel design. Two different treatments will be evaluated e.g. a 18-day intervention with fermotein based meals and a 18-day intervention with control meals. At the start and at the end of the intervention, a blood sample will be collected. Questionnaires about gut complaints, stool consistency and frequency, wellbeing, health complaints or other adverse effects will be collected daily during intervention and up to two days after the intervention.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Wageningen, Gelderland, 6708 WG, Netherlands
Fermotein™ is a mycoprotein, derived from fungi, especially produced for human consumption. It is high in protein, high in fiber, low in saturated fat and contains no cholesterol. Its functional properties and nutrient content makes them ideal to use as an ingredient for meat alternatives and other vegetarian/vegan food products. This study aims to assess the impact of frequent intake of 11 grams of Fermotein™ powder (dry) on gastrointestinal complaints and several other health related biomarkers.
The primary objective is to investigate gastro-intestinal complaints during 18 days of Fermotein™ consumption. The secondary objective is to assess blood based parameters related to general health and consumer acceptance.
The study has a randomized parallel design. Two different treatments will be evaluated e.g. a 18-day intervention with Fermotein™ based meals and a 18-day intervention with control meals. At the start and at the end of the intervention a blood sample will be collected. Questionnaires about gut complaints, stool consistency and frequency, wellbeing, health complaints or other adverse effects will be collected daily during intervention and up to two days after the intervention.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
various meal products: bread, soup and an occasional burgers
various meal products: bread, soup and an occasional burgers
Time frame: Daily, during 18 days of Fermotein™ intake and up to three days after intake.
Determined by combining multiple outcome measures ( bloated feeling, belching, abdominal pain, flatulence, nausea, diarrhoea, constipation) measured via questionnaires with Visual Analogue Scale (VAS) scores; from no complaints (minimal) to serious complaints (maximum). Higher values represent a worse outcome.
Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption
under fasting conditions
Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption
under fasting conditions
Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption
under fasting conditions
Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption
under fasting conditions
Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption
under fasting conditions
Time frame: before and after 18 days consumption of Fermotein™ or control product
under fasting conditions
Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption
under fasting conditions
Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption
under fasting conditions
Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption
under fasting conditions
Time frame: at baseline, and after 18 days of fermotein or control product consumption
under fasting conditions
Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption
under fasting conditions
Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption
under fasting conditions
Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption
systolic and diastolic bloodpressure
Wageningen University and Research
Other
Tolerance of Regular Meal Intake With Mycoprotein
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07125482
Gastrointestinal Complication, Palliative Care, Patient Care
Kahramanmaraş, Turkey (Türkiye)
View Trial DetailsNCT04192435
Anesthesia, Bleeding
Melbourne, Victoria, Australia
View Trial DetailsNCT06165523
Aerobic Endurance, Exercise Performance
Saint Charles, Missouri, United States
View Trial DetailsNCT03678987
Connective Tissue Diseases, Gastrointestinal Complication
Lund, Sweden
View Trial Details